NJ-METLIFE/AIM
29.8.2022 14:01:57 CEST | Business Wire | Press release
MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), announced that it has entered into a definitive agreement to acquire Affirmative Investment Management (AIM), a specialist global environmental, social and corporate governance (ESG) impact fixed income investment manager with deep capabilities in impact investing, verification, reporting and engagement. As of June 30, 2022, AIM’s assets under management were $1.01 billion. The acquisition is subject to customary closing conditions, including regulatory approval.
The acquisition will advance MIM’s ESG investment and reporting capabilities as it seeks to deliver client solutions and long-term risk adjusted returns. “By combining AIM’s expertise with MIM’s commitment to sustainable investing, we will be even better positioned to provide comprehensive insight and counsel to clients and consultants on ESG considerations,” said Steven J. Goulart, president of MIM and executive vice president and chief investment officer for MetLife. “MIM will maintain its fundamental investment processes, and AIM brings us additional capabilities to evaluate sustainability and risk considerations across our core competencies in public fixed income, private fixed income and real estate.”
“We are pleased to be able to join a world-class institutional investment firm in MIM and continue our mission of managing high-performing portfolios that consider positive environmental and social impact,” said Stephen Fitzgerald, who co-founded AIM in 2014. “Upon our planned integration with MIM’s investment teams, we believe that we can deliver differentiated insights and analysis to MIM’s growing roster of global clients.”
AIM has won numerous ESG related industry awards, most recently Best ESG Investment Fund: Fixed Income at the ESG Investing Awards 2022, Impact Asset manager of the Year at the 2021 Australian Impact Investment Awards, and Impact Report of the Year (for investors) at the Environmental Finance Bond Awards in 2021.
About MetLife Investment Management
MetLife Investment Management, the institutional asset management business of MetLife, Inc. (NYSE: MET), is a global public fixed income, private capital and real estate investment manager providing tailored investment solutions to institutional investors worldwide. MetLife Investment Management provides public and private pension plans, insurance companies, endowments, funds and other institutional clients with a range of bespoke investment and financing solutions that seek to meet a range of long-term investment objectives and risk-adjusted returns over time. MetLife Investment Management has over 150 years of investment experience and, as of June 30, 2022, had $590.9 billion in total assets under management.
About MetLife
MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com.
About Affirmative Investment Management
Affirmative Investment Management (AIM) is a specialist global environmental, social and corporate governance (ESG) impact fixed income investment manager with deep capabilities in impact investing, verification, reporting and engagement. Established in 2014, AIM focuses on mobilizing mainstream capital to address ESG-related challenges. Its mission is to manage fixed income portfolios that generate positive environmental and social impact without compromising financial returns. AIM’s highly experienced team is solely focused on investing in, and expanding, the impact bond market with a rigorous approach to building impact bond portfolios and generating returns.
Forward-Looking Statements
The forward-looking statements in this news release, using words such as “will,” “seek,” “continue,” “planned,” “believe” and “can” are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it does not undertake any obligation to correct or update any of these statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005211/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Delivers Fourth Quantum Computer in Finland, Operational at Aalto University11.3.2026 11:32:00 CET | Press release
This is the fourth quantum computer deployed by IQM to customers in Finland to boost research and education in a growing ecosystem. The system named Aalto Q20 quantum computer is online at Aalto University and will enable students and scientists a unique first-hand access to a world-class quantum computer. The university will use the quantum computer to perform scientific experiments on advanced level and to support national and European quantum research activities. IQM Quantum Computers, the global leader in deployed on-premises, full-stack superconducting quantum computers, today announced the launch of Aalto Q20 quantum computer in Finland, reinforcing its commercial leadership in the quantum industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311215316/en/ Ribbon cutting of the Aalto Q20 quantum computer delivered by IQM. The 20-qubit system, which is operational at Aalto University, is the fourth quantum compute
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site11.3.2026 11:00:00 CET | Press release
Highlights Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients retain continuity of care while reducing carbon emissionsBespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resiliencePartnership aligns with the science-based climate commitments of both companies Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program. This press release features multi
NTT DATA Unveils NVIDIA-Powered Enterprise AI Factories to Support Secure AI Adoption and Help Clients Drive Measurable ROI11.3.2026 11:00:00 CET | Press release
NTT DATA drives success in healthcare, manufacturing and other sectors with NVIDIA-powered technologies NTT DATA AI solutions now integrate NVIDIA AI Enterprise software, including NVIDIA NeMo and NIM Microservices to create a full-stack, production-ready, GPU-accelerated agentic AI platform NTT DATA, a global leader in AI, digital business and technology services, announced an initiative to deliver NVIDIA-powered enterprise AI factories that drive innovation and operational excellence for organizations worldwide. NTT DATA’s new enterprise AI factories provide full-stack, domain-specific solutions that integrate data, infrastructure, workflows and governance to give organizations a repeatable and production-ready operating model for enterprise AI. NTT DATA enterprise AI factories, powered by NVIDIA, are adaptive, intelligent and automated ecosystems designed to help clients accelerate return on investment by scaling enterprise AI efficiently and managing the full AI lifecycle end to en
Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health11.3.2026 10:00:00 CET | Press release
£65m investment in new oral health manufacturing plant in Shanghai to support growth in the world’s largest gum health market Haleon aiming to extend gum health brand parodontax to 30 Chinese cities by end of 2027 - including its fastest growing cities – reaching aspirational shoppers in-store and online Custom designed taste, foamier sensation and premium packaging to appeal to local consumers Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples11.3.2026 09:00:00 CET | Press release
Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expertise to reducing diagnostic uncertainty with solutions that support clinicians and laboratories nationwide and internationally. Eurofins Biomnis has fully validated the method for human stool samples, taking into account matrix effects and meeting the requirements of ISO 15189 (with the exception of inter‑method comparison on pathological clinical samples). Cereulide, a toxin produced by specific strains of Bacillus cereus, has recently raised significant public attention following contamination events involving infant formula
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom